Diuretics & Volume Management
Core concept: Diuretics increase renal sodium excretion at different nephron sites, and their clinical effect depends on drug delivery, kidney function, sodium exposure, and compensatory nephron responses.
Key clinical distinction: The same creatinine rise can occur during persistent congestion or after excessive volume removal; the treatment response is different.
Prescribing priority: Treat the patient’s volume and perfusion state—not edema, urine output, or creatinine in isolation—and intensify laboratory monitoring when combining nephron sites.
Think in Terms of Nephron Site and Treatment Goal
| Class | Primary site/action | Examples | Major clinical role |
|---|---|---|---|
| Loop | Na+/K+/2Cl- cotransporter, thick ascending limb | Furosemide, bumetanide, torsemide | Moderate-to-severe congestion; heart-failure volume management |
| Thiazide / thiazide-like | Na+/Cl- cotransporter, distal convoluted tubule | hydrochlorothiazide, chlorthalidone, indapamide, metolazone | Hypertension; sequential nephron blockade |
| ENaC-blocking potassium-sparing | Epithelial sodium channel, distal nephron | Amiloride, triamterene | Potassium conservation; limited natriuresis |
| Mineralocorticoid receptor antagonist | Blocks aldosterone signaling | Spironolactone, eplerenone | Heart failure with reduced ejection fraction (HFrEF) disease modification; resistant hypertension; selected HF phenotypes |
Loop diuretics are the principal agents for clinically important heart-failure congestion. Thiazide and thiazide-like agents are major antihypertensive drugs and can augment loop therapy when natriuresis is inadequate. Amiloride and triamterene produce comparatively little natriuresis when used alone. Steroidal MRAs are weak diuretics; their importance in HFrEF is primarily neurohormonal and disease-modifying (Williams et al., 2026; Ng & Yeung, 2026).
Loop Diuretics
Furosemide, bumetanide, and torsemide inhibit the Na+/K+/2Cl- cotransporter in the thick ascending limb of Henle and are the most potent commonly used diuretics for clinically important congestion (Ng & Yeung, 2026).
Approximate oral potency: furosemide 40 mg ≈ torsemide 20 mg ≈ bumetanide 1 mg
These are potency relationships rather than universally interchangeable patient doses. Furosemide has more variable oral bioavailability than bumetanide or torsemide; torsemide has a longer duration. No loop diuretic has established mortality superiority over another when equivalent therapy is used (Ng & Yeung, 2026).
Why Kidney Function Changes the Required Dose
Loop diuretics must reach the tubular lumen through active secretion. Reduced kidney function and competing organic acids can reduce tubular delivery, so greater loop exposure may be required to reach the diuretic threshold. Reduced eGFR therefore changes dose-response; it does not mean the kidney is incapable of responding (Ng & Yeung, 2026).
Loop-Diuretic Adverse Effects
- Hypovolemia and hypotension
- Hyponatremia
- Hypokalemia and hypomagnesemia
- Worsening renal function
- Hyperuricemia and gout
- Metabolic alkalosis
- Excessive preload reduction with organ hypoperfusion
Ototoxicity is uncommon with standard loop-diuretic therapy but is a recognized risk, especially with ethacrynic acid and with rapid intravenous or very high-dose furosemide exposure (Stamatakis, 2026).
Thiazide and Thiazide-Like Diuretics
Thiazide and thiazide-like agents reduce sodium and chloride reabsorption in the distal convoluted tubule. Chlorthalidone, hydrochlorothiazide, and indapamide are major antihypertensive drugs; metolazone is especially useful when loop therapy requires augmentation. Chlorthalidone has greater potency and longer duration than hydrochlorothiazide, but selection should account for electrolyte vulnerability, adherence, and response rather than treating one agent as universally superior (Williams et al., 2026).
- Hypokalemia and hypomagnesemia
- Hyponatremia
- Hyperuricemia and gout
- Hypercalcemia
- Small adverse effects on glucose or lipid metabolism in susceptible patients
High-yield electrolyte distinction: thiazide therapy can increase serum calcium, whereas loop therapy can promote hypocalcemia; both classes can lower potassium and magnesium (Williams et al., 2026).
Thiazides and Reduced Kidney Function
Thiazide efficacy generally declines as kidney function worsens, but reduced eGFR is not an absolute class cutoff. Some thiazide-like agents retain clinically meaningful activity in advanced CKD. Metolazone remains useful at reduced renal function and is frequently paired with a loop diuretic during diuretic resistance (Williams et al., 2026; Ng & Yeung, 2026).
Sequential Nephron Blockade
Chronic loop blockade increases distal sodium delivery and downstream sodium reclamation. When adequate loop exposure does not produce the desired natriuresis, adding a second nephron-site drug can restore response. Common strategies include a loop plus metolazone or IV chlorothiazide, and in selected acute HF patients a loop plus acetazolamide (Ng & Yeung, 2026).
The same strategy increases risk of hyponatremia, hypokalemia, hypomagnesemia, hypotension, excessive volume depletion, and worsening renal function. Adding a second diuretic therefore requires more—not less—monitoring.
Do Not Assume Diuretic Resistance Means “Give More Diuretic”
- Insufficient loop dose or poor oral absorption
- Reduced tubular drug delivery
- High dietary sodium intake or nonadherence
- NSAID exposure
- Compensatory distal sodium reabsorption
- Systemic/renal venous congestion
- Reduced renal perfusion or low cardiac output
Mechanism matters. A still-congested patient with adequate perfusion and distal nephron adaptation may benefit from sequential blockade; a hypotensive patient with poor renal perfusion may deteriorate with escalating volume removal (Ng & Yeung, 2026).
Potassium-Sparing Diuretics
Amiloride and triamterene block epithelial sodium channels in the distal nephron and produce limited diuresis. Their major use is potassium conservation. Hyperkalemia risk rises with CKD, ACE inhibitors, ARBs, ARNIs, MRAs, potassium supplements, and NSAIDs (Williams et al., 2026).
Mineralocorticoid Receptor Antagonists
Spironolactone and eplerenone block aldosterone. In symptomatic HFrEF they reduce morbidity and mortality and should not be conceptualized merely as potassium-sparing diuretics. For HFrEF, usual safety criteria include potassium <5 mEq/L and eGFR >30 mL/min/1.73 m² (Ng & Yeung, 2026).
Check potassium and renal function before treatment, at approximately day 3 and 1 week after initiation or titration, monthly for the first 3 months, then about every 3 months or more often when clinical risk is high. Spironolactone can cause gynecomastia and other endocrine effects; eplerenone is more receptor-selective but is a CYP3A4 substrate and should not be used with strong CYP3A4 inhibitors (Ng & Yeung, 2026).
Volume Management in Heart Failure
The goal is euvolemia—not maximum urine output. Improvement should occur in congestion-related symptoms and signs such as dyspnea, orthopnea, elevated JVP, edema, pulmonary congestion, abdominal congestion, and excess volume-related weight. Once euvolemia is achieved, use the lowest diuretic dose that maintains it (Ng & Yeung, 2026).
When Creatinine Rises During Diuresis
- Is the patient still congested?
- Is blood pressure and organ perfusion adequate?
- Have dyspnea, JVP, edema, and weight improved?
- Has decongestion gone too far?
A creatinine change alone does not identify the mechanism. Persistent congestion and excessive volume removal can both coexist with worsening renal indices but require different responses. Overdiuresis can produce hypotension and organ hypoperfusion (Ng & Yeung, 2026).
High-Yield Distinctions
- Loop diuretics are the principal agents for significant HF congestion.
- Thiazide/thiazide-like agents are major antihypertensive drugs and can augment loop therapy.
- Reduced kidney function may require greater loop exposure rather than abandonment of loop therapy.
- Sequential nephron blockade improves natriuresis but raises electrolyte and volume-depletion risk.
- Steroidal MRAs are disease-modifying HFrEF therapies, not merely weak diuretics; eplerenone is a CYP3A4 substrate and should not be used with strong CYP3A4 inhibitors.
- Urine output is a treatment response, not the treatment goal.
- A creatinine rise during decongestion must be interpreted with congestion and perfusion.
Related YourDNP Resources
Content last reviewed:
References
Ng, T. M. H., & Yeung, S. L. (2026). Heart failure. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 184–238). McGraw Hill.
Stamatakis, M. K. (2026). Acute kidney injury. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 854–877). McGraw Hill.
Williams, C., Finks, S. W., & Chisholm-Burns, M. A. (2026). Hypertension. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 139–183). McGraw Hill.